UBS Group’s Can-Fite BioPharma American Depositary Shares CANF Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-2,152
| Closed | -$6.67K | – | 10486 |
|
|
2026
Q1 | $6.67K | Buy |
2,152
+1,105
| +106% | +$4.57K | ﹤0.01% | 8666 |
|
|
2025
Q4 | $4.19K | Buy |
1,047
+982
| +1,511% | +$7.7K | ﹤0.01% | 8878 |
|
|
2025
Q3 | $810 | Sell |
65
-211
| -76% | -$3.22K | ﹤0.01% | 9537 |
|
|
2025
Q2 | $5.79K | Buy |
+276
| New | +$6.36K | ﹤0.01% | 9136 |
|
|
2024
Q2 | – | Sell |
-109
| Closed | -$4.82K | – | 9560 |
|
|
2024
Q1 | $4.82K | Buy |
+109
| New | +$4.55K | ﹤0.01% | 7590 |
|
|
2023
Q2 | – | Sell |
-36
| Closed | -$1.64K | – | 8970 |
|
|
2023
Q1 | $1.64K | Sell |
36
-8
| -18% | -$575 | ﹤0.01% | 8688 |
|
|
2022
Q4 | $5.31K | Sell |
44
-43
| -49% | -$6.67K | ﹤0.01% | 9194 |
|
|
2022
Q3 | $13K | Buy |
87
+49
| +129% | +$8.49K | ﹤0.01% | 8010 |
|
|
2022
Q2 | $7K | Buy |
38
+2
| +6% | +$384 | ﹤0.01% | 8460 |
|
|
2022
Q1 | $9K | Buy |
+36
| New | +$8.31K | ﹤0.01% | 8533 |
|
|
2021
Q3 | – | Sell |
-39
| Closed | -$18K | – | 9568 |
|
|
2021
Q2 | $18K | Buy |
+39
| New | +$17.1K | ﹤0.01% | 7441 |
|
|
2020
Q3 | – | Sell |
-15
| Closed | -$6K | – | 8007 |
|
|
2020
Q2 | $6K | Sell |
15
-28
| -65% | -$10.3K | ﹤0.01% | 7283 |
|
|
2020
Q1 | $11K | Buy |
43
+39
| +975% | +$14.9K | ﹤0.01% | 6853 |
|
|
2019
Q4 | $2K | Buy |
+4
| New | +$2.15K | ﹤0.01% | 7820 |
|
|
2019
Q1 | – | Sell |
-1
| Closed | -$2K | – | 7751 |
|
|
2018
Q4 | $2K | Buy |
+1
| New | +$3.86K | ﹤0.01% | 7790 |
|
|
2018
Q3 | – | Sell |
-1
| Closed | -$3.75K | – | 7731 |
|
|
2018
Q2 | $3K | Buy |
+1
| New | +$3.99K | ﹤0.01% | 7619 |
|
|
2018
Q1 | – | Hold |
0
| – | -$1K | – | 7823 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 7694 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 7459 |
|
|
2017
Q1 | – | Sell |
-1
| Closed | -$6K | – | 7652 |
|
|
2016
Q4 | $6K | Buy |
+1
| New | +$7.01K | ﹤0.01% | 7145 |
|
|
2016
Q3 | – | Sell |
-2
| Closed | -$13.9K | – | 7504 |
|
|
2016
Q2 | $16K | Buy |
+2
| New | +$16.9K | ﹤0.01% | 6452 |
|
|
2015
Q3 | – | Sell |
-2
| Closed | -$11K | – | 8415 |
|
|
2015
Q2 | $11K | Buy |
2
+1
| +100% | +$7K | ﹤0.01% | 7379 |
|
|
2015
Q1 | $5K | Buy |
+1
| New | +$12K | ﹤0.01% | 8083 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 9524 |
|
Other funds holding CANF
AWM
TWC
UBS Group's CANF Position: Q2 2026 in Review
UBS Group sold out of Can-Fite BioPharma American Depositary Shares (CANF) in Q2 2026, closing a stake of 2,152 shares — an estimated $6.67K sold.
UBS Group first reported a position in CANF in Q1 2015 and held it in 20 quarters. The position peaked at $18K in Q2 2021. 8 funds tracked by Wall St. Rank hold CANF as of Q2 2026.
- UBS Group reported no remaining Can-Fite BioPharma American Depositary Shares position as of Q2 2026 after selling out during the quarter.
- UBS Group sold 2,152 Can-Fite BioPharma American Depositary Shares shares in Q2 2026, an estimated $6.67K.
- UBS Group first reported a position in Can-Fite BioPharma American Depositary Shares in Q1 2015 and held it in 20 quarters.
- UBS Group's Can-Fite BioPharma American Depositary Shares position peaked at $18K in Q2 2021.
- 8 funds tracked by Wall St. Rank held Can-Fite BioPharma American Depositary Shares as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.